NasdaqGM:OCULPharmaceuticals
Ocular Therapeutix Data Strengthens AXPAXLI Durability Case And FDA Ambitions
Ocular Therapeutix (NasdaqGM:OCUL) released new 52-week post hoc Phase 3 data for AXPAXLI in wet age-related macular degeneration.
The SOL-1 trial data indicated better durability, strong sustained disease control, and safety outcomes compared to aflibercept.
The company presented the findings at a major ophthalmology conference and plans to seek FDA approval with a single pivotal Phase 3 trial.
Ocular Therapeutix focuses on therapies for eye diseases, with AXPAXLI (OTX TKI) aimed at...